
Havas N.V. is actively executing its €50 million share buyback program, having repurchased over 7.1 million shares totaling €10.7 million since May 2025. This capital allocation strategy aligns with the company's H1 2025 results, which saw Q2 organic growth of 2.6% and exceeded EBITA forecasts, despite unadjusted net income falling short. Analyst sentiment is positive, with Goldman Sachs initiating a Buy rating and EUR1.90 price target, citing strong risk/reward and growth potential, while InvestingPro considers the stock undervalued with an attractive 5.4% dividend yield.
Havas N.V. is actively executing its €50 million share repurchase program, having already deployed approximately €10.7 million to buy back over 7.1 million shares at an average price of €1.4896, well below the current trading price of €1.75. This capital return strategy is supported by recent financial performance, where the company posted 2.6% organic growth in Q2 2025, slightly ahead of the 2.5% analyst consensus. While H1 results showed EBITA exceeding forecasts, unadjusted net income fell short of projections, indicating a mixed but generally stable operational picture. Confidence in the outlook is underscored by management's decision to maintain full-year 2025 guidance. The bullish case is further reinforced by new coverage from Goldman Sachs, which initiated with a Buy rating and a €1.90 price target, citing a strong risk/reward profile, solid balance sheet, and healthy revenue exposure, with 29% coming from the Health sector. The stock's current valuation appears attractive, with a P/E ratio of 8.4x and a compelling dividend yield of 5.4%, suggesting potential undervaluation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment